Respuesta clínica a la quimioterapia neoadyuvante en los pacientes diagnosticados de cáncer de mama en estadio III en SOLCA Loja durante el periodo 2010 - 2014

Abstract

Abstract: The general objective of the present project is to evaluate the clinical response of patients diagnosed in stage III breast cancer treated with neoadjuvant chemotherapy in SOLCA Loja between January 2010-December 2014, to determinate the grade of effectiveness through the postoperative histopathological study. Data from 87 clinical histories of patients with stage III (locally advanced) breast cancer were collected (27,6%); in this group, 36 patients who received neoadjuvant chemotherapy (41,38%) were included. In the sample studied, stage III breast cancer appears more frequently in women between the ages of 60 and 69 years old (33,33%) in urban areas. The best response observed was the lowest complete response (RCM) at 19,44%. The majority of cases (64%) had a partial response (PR) and 5,56% had no response (NR). It should be emphasized that there were no patients who developed a complete response (RC). According to immunohistochemistry, RCm was presented in HER2/neu + and luminal A (8.3%), followed by luminal B (2.8%). Luminal A and triple negative types did not develop any response (NR) in the 2.8%, respectively.